Signal from the log
Epicrispr Biotechnologies
90 M$ · Series C · United States · Biotech
Biotech américaine qui développe EPI-321, une édition épigénétique fondée sur CRISPR : elle éteint un gène sans couper l'ADN. La cible est la dystrophie facio-scapulo-humérale, en réduisant l'expression du gène DUX4 responsable de la fonte musculaire.
Verified
Announced on , logged by the watch of 11 August 2026.
- Operation
- Funding round
- Announced amount
- 90 M$
- Stage
- Series C
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Octagon Capital , Janus Henderson Investors , with Fidelity Management & Research , Sanofi Ventures , Cormorant Asset Management
Provenance
Logged on 11 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.